bromide has been researched along with Hyperidrosis in 6 studies
Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis." | 9.41 | A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021) |
| "A long-term study was conducted in Japanese patients with primary axillary hyperhidrosis who completed the preceding 6-week phase III, confirmatory study of 5% sofpironium bromide gel (hereinafter referred to as sofpironium) to evaluate the safety and efficacy of 52-week treatment with sofpironium." | 9.41 | A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021) |
| "A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI-4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis." | 5.41 | A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021) |
| "A long-term study was conducted in Japanese patients with primary axillary hyperhidrosis who completed the preceding 6-week phase III, confirmatory study of 5% sofpironium bromide gel (hereinafter referred to as sofpironium) to evaluate the safety and efficacy of 52-week treatment with sofpironium." | 5.41 | A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. ( Abe, Y; Akamatsu, M; Egami, Y; Fujimoto, T; Hamaguchi, M; Hanafusa, T; Hattori, N; Horiuchi, Y; Igarashi, M; Ishikoh, A; Kanda, H; Kinoshita, M; Kitahara, H; Kume, A; Maruyama, R; Matsuda, T; Matsuo, K; Mizutani, H; Murakami, Y; Nakasu, I; Omi, T; Takayama, S; Watanabe, C; Yokozeki, H; Yorozuya, T; Yoshioka, A, 2021) |
| " The soft anticholinergic sofpironium bromide represents the latest expansion of soft drug use in dermatology for the treatment of primary axillary hyperhidrosis (PAH)." | 4.12 | SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design. ( Armstrong, A; Chadha, D; Kircik, L; Reddy, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gregoriou, S | 1 |
| Tsiogka, A | 1 |
| Kontochristopoulos, G | 1 |
| Offidani, A | 1 |
| Campanati, A | 1 |
| Armstrong, A | 1 |
| Reddy, R | 1 |
| Chadha, D | 1 |
| Kircik, L | 1 |
| Fujimoto, T | 3 |
| Okatsu, H | 1 |
| Miyama, H | 1 |
| Paik, J | 1 |
| Yokozeki, H | 2 |
| Abe, Y | 2 |
| Igarashi, M | 2 |
| Ishikoh, A | 2 |
| Omi, T | 2 |
| Kanda, H | 2 |
| Kitahara, H | 2 |
| Kinoshita, M | 2 |
| Nakasu, I | 2 |
| Hattori, N | 2 |
| Horiuchi, Y | 2 |
| Maruyama, R | 2 |
| Mizutani, H | 2 |
| Murakami, Y | 2 |
| Watanabe, C | 2 |
| Kume, A | 2 |
| Hanafusa, T | 2 |
| Hamaguchi, M | 2 |
| Yoshioka, A | 2 |
| Egami, Y | 2 |
| Matsuo, K | 2 |
| Matsuda, T | 2 |
| Akamatsu, M | 2 |
| Yorozuya, T | 2 |
| Takayama, S | 2 |
1 review available for bromide and Hyperidrosis
| Article | Year |
|---|---|
Sofpironium Bromide: First Approval.
Topics: Bromides; Cholinergic Antagonists; Gels; Humans; Hyperhidrosis; Japan | 2020 |
2 trials available for bromide and Hyperidrosis
| Article | Year |
|---|---|
A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Topics: Adult; Axilla; Bromides; Double-Blind Method; Female; Humans; Hyperhidrosis; Japan; Male; Severity o | 2021 |
A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Topics: Adult; Bromides; Double-Blind Method; Female; Humans; Hyperhidrosis; Japan; Male; Treatment Outcome | 2021 |
3 other studies available for bromide and Hyperidrosis
| Article | Year |
|---|---|
Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis.
Topics: Axilla; Bromides; Cholinergic Antagonists; Drugs, Investigational; Humans; Hyperhidrosis; Treatment | 2022 |
SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design.
Topics: Bromides; Cholinergic Antagonists; Drug Design; Humans; Hyperhidrosis; Pharmaceutical Preparations | 2022 |
Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
Topics: Adult; Axilla; Bromides; Cholinergic Antagonists; Female; Humans; Hyperhidrosis; Japan; Male; Prospe | 2022 |